• where experts go to learn about FDA
  • Larry K. Houck

    • Registered EMS Agencies: The New Kid on the DEA BlockFebruary 10th, 2026

      The Drug Enforcement Administration (“DEA”) has welcomed a new category of registrant: emergency medical services (“EMS”) agencies.  DEA has finalized its regulations to conform with the Protecting Patient Access to Emergency Medications Act of 2017 (“the Act”), establishing a new registrant category, registration standards and …

    • Changes to “Hemp” Definition Set to Close the Farm Bill LoopholeJanuary 21st, 2026

      President Donald Trump’s Executive Order directed the Attorney General last month to expedite the completion of marijuana rescheduling, but also mandated that the Administration work with Congress to update the statutory definition of final hemp-derived cannabidiol (“CBD”) products for medical use of full spectrum CBD.  …

    • Prescribing/Dispensing “Outside the Usual Course of Professional Practice:” Trend, Coincidence or Passing Fancy?January 7th, 2026

      We follow the civil settlements agreed to by the Drug Enforcement Administration (“DEA”) and registrants that are announced in press releases by U.S. Attorney’s Offices and DEA.  We were interested to observe what appeared to be a recurring theme running through four of the six …

    • E.O. Directs AG to Complete Marijuana Schedule III ReschedulingDecember 24th, 2025

      President Donald Trump signed an Executive Order on Thursday last week directing the Attorney General to expedite completion of marijuana rescheduling begun in October 2022 to facilitate medical research.  There was uncertainty whether President Trump, now in the White House, would support rescheduling.  Candidate Trump …

    • New Rules, New Risks: Inside the Changing World of Federal InspectionsNovember 11th, 2025

      Hyman, Phelps & McNamara, P.C. (“HPM”) Director Larry Houck will moderate “New Rules, New Risks: Inside the Changing World of Federal Inspections” at the Food and Drug Law Institute’s Enforcement, Litigation, and Compliance Conference in Washington, D.C., December 4-5, 2025.  The session will explore the …

    • Bring Out Your Meds! Bring Out Your Meds!October 22nd, 2025

      With a nod to the immortal phrase, “Bring out your dead!  Bring out your dead!” uttered by body collector Eric Idle from the 1975 comedy romp, Monty Python and the Holy Grail, in calling attention to Drug Enforcement Administration’s 29th National Prescription Drug Take Back …

    • 1972 Washington Redskins Led Sweep of Anti-Drug Public Service CampaignOctober 13th, 2025

      I became a Diversion Investigator with the Drug Enforcement Administration (“DEA”) in 1986, but it only recently dawned on me that my relationship with the agency actually began as a ninth grader about 14 years earlier.  In 1972, DEA’s predecessor, the Bureau of Narcotics and …

    • California’s Novel Approach to Controlled Substance Inventory and Loss ReportingSeptember 25th, 2025

      The California Board of Pharmacy (the “Board”) implemented a novel approach to address employee theft as one aspect of the opioid epidemic in 2018 by requiring pharmacies and clinics to reconcile their quarterly schedule II inventories.  The approach was novel because to our knowledge, no …

    • Internal Mock DEA-Style and Mirror Inspections and Audits: Trust But VerifySeptember 9th, 2025

      Drug Enforcement Administration (“DEA”) diversion investigators conduct random, unannounced cyclic inspections of “non-practitioner” registrants (manufacturers, distributors, importers, exporters and narcotic treatment programs) about every three years.  Investigators also randomly inspect hospitals, pharmacies and practitioners.  With civil monetary penalties for violations of recordkeeping and reporting requirements …

    • Cannabis Redux: Marijuana Rescheduling Act Reintroduced in the U.S. HouseSeptember 3rd, 2025

      On the heels of President Donald Trump saying that he is considering executive action on marijuana rescheduling determination, Representative Greg Steube (R-Florida) reintroduced his Marijuana 1-to-3 Act that would legislatively reschedule marijuana from schedule I under the federal Controlled Substances Act (“CSA”) to schedule III.  …

    • DEA Registrants: Put Your Best Foot Forward By Creating An Inspection BinderAugust 19th, 2025

      Like death and taxes, unannounced, periodic cyclic inspections of controlled substance manufacturers, distributors, importers, exporters, and narcotic treatment programs, by Drug Enforcement Administration (“DEA”) diversion investigators every three to five years is inevitable.  “Practitioner” registrants, that include hospitals, pharmacies, and practitioners, are also subject to …

    • A Tip of the Hat to Retiring DEA Chief ALJ MulrooneyJuly 31st, 2025

      Earlier this week, we posted on the retirement of DEA Chief Administrative Law Judge Judge John J. Mulrooney, II, and the lack of appointed DEA ALJs to hear DEA cases upon his retirement, effective August 1.  On a related note, HPM wants to take a …

    • Oyez, Oyez, Oyez! Effective August 1, DEA Will Have No Administrative Law JudgesJuly 28th, 2025

      Last week, DEA registrants and applicants with pending actions before DEA’s Office of Administrative Law Judges (OALJ) received an order from Chief Administrative Law Judge John J. Mulrooney, II, staying the hearing proceedings in those cases.  In those orders, Chief Judge Mulrooney announced that he …

    • Controlled Substance Reporting Isn’t Just for DEA AnymoreJuly 1st, 2025

      A memorable Florida Orange Growers’ television ad campaign in the late 1970s proclaimed that “Orange juice from Florida isn’t just for breakfast anymore.” The Federal Controlled Substances Act (“CSA”) and its regulations require Drug Enforcement Administration (“DEA”) registrants to submit certain reports related to narcotic …

    • DEA Cranks Out Updated Special Surveillance List and Proposed Regulatory ActionsJune 11th, 2025

      Special Surveillance List of Chemicals, Products, Materials and Equipment Updated A “laboratory supply” is any List I or List II chemical, or any chemical, substance, or other item on a special surveillance list published by the Attorney General (delegated to the Drug Enforcement Administration (“DEA”)) of …